These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9171223

  • 1. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
    Buckheit RW, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch LA, Roberson J, Decker W, Elder C, Borgel S, Bonomi C, Shores R, Siford T, Malspeis L, Bader JP.
    AIDS Res Hum Retroviruses; 1997 Jun 10; 13(9):789-96. PubMed ID: 9171223
    [Abstract] [Full Text] [Related]

  • 2. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
    Buckheit RW, Snow MJ, Fliakas-Boltz V, Kinjerski TL, Russell JD, Pallansch LA, Brouwer WG, Yang SS.
    Antimicrob Agents Chemother; 1997 Apr 10; 41(4):831-7. PubMed ID: 9087499
    [Abstract] [Full Text] [Related]

  • 3. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
    Borkow G, Arion D, Wainberg MA, Parniak MA.
    Antimicrob Agents Chemother; 1999 Feb 10; 43(2):259-63. PubMed ID: 9925515
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.
    Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA.
    J Virol; 1997 Apr 10; 71(4):3023-30. PubMed ID: 9060662
    [Abstract] [Full Text] [Related]

  • 6. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A, Bader JP.
    Antimicrob Agents Chemother; 1999 Aug 10; 43(8):1827-34. PubMed ID: 10428899
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.
    J Virol; 2001 Jun 10; 75(11):4999-5008. PubMed ID: 11333879
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.
    Barnard J, Borkow G, Parniak MA.
    Biochemistry; 1997 Jun 24; 36(25):7786-92. PubMed ID: 9201921
    [Abstract] [Full Text] [Related]

  • 14. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.
    Antiviral Res; 2006 Jun 24; 70(2):66-74. PubMed ID: 16472877
    [Abstract] [Full Text] [Related]

  • 15. Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.
    Kang D, Sun Y, Feng D, Gao S, Wang Z, Jing L, Zhang T, Jiang X, Lin H, De Clercq E, Pannecouque C, Zhan P, Liu X.
    J Med Chem; 2022 Feb 10; 65(3):2458-2470. PubMed ID: 35061384
    [Abstract] [Full Text] [Related]

  • 16. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
    McMahon JB, Buckheit RW, Gulakowski RJ, Currens MJ, Vistica DT, Shoemaker RH, Stinson SF, Russell JD, Bader JP, Narayanan VL, Schultz RJ, Brouwer WG, Felauer EE, Boyd MR.
    J Pharmacol Exp Ther; 1996 Jan 10; 276(1):298-305. PubMed ID: 8558446
    [Abstract] [Full Text] [Related]

  • 17. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
    He Y, Chen F, Yu X, Wang Y, De Clercq E, Balzarini J, Pannecouque C.
    Bioorg Chem; 2004 Dec 10; 32(6):536-48. PubMed ID: 15530994
    [Abstract] [Full Text] [Related]

  • 18. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Cao YL, Li SX, Chen H, Guo Y.
    Yao Xue Xue Bao; 2009 Apr 10; 44(4):355-61. PubMed ID: 19545051
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.